Close
Almac
Achema middle east

Kuehne+Nagel new airside facility boosts Africa’s healthcare logistics capability

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

First GLP-1 Pill for Obesity by Novo Nordisk Approved by FDA

The U.S. Food and Drug Administration – FDA on...

How High-Achievers Stay Future-Ready in Evolving Job Markets

Job markets today are transforming rapidly. In the past...

Proactive Risk Management as a Core Capability in Pharma Development

Risk management in pharma is often treated as a reactive compliance box-ticking exercise. This article argues for reframing risk as a strategic competitive advantage. It details proactive frameworks like the "Excipient Exclusion Filter," Decision Quality (DQ) matrices, and "pre-mortem" analyses that allow development teams to anticipate failure modes and engineer them out of the pipeline before they occur.
- Advertisement -

Kuehne+Nagel has entered into a long-term agreement for a new airside facility strategically located in the airport zone of OR Tambo International airport, Johannesburg, South Africa – the largest and busiest airport in Africa. As part of this agreement, Kuehne+Nagel offers customers a set of logistics solutions, including warehousing, transportation, customs brokerage, supply chain management, and airside support to project-specific charter in- and outbound shipments. Core to this offering is a comprehensive cold chain solution, ensuring around-the-clock temperature-control to safeguard the integrity of highly sensitive pharma products.

The new offering is pivotal to supporting Africa’s aim to become more self-reliant in healthcare operations. South Africa, Nigeria, and Algeria are leading the manufacturing charge in sub-Saharan Africa, while imports from Europe, North America, India and China remain crucial to meeting Africa’s demand for medicines and basic healthcare. To support its healthcare customers – both importers and manufacturers – in executing their strategic growth plans for Africa, Kuehne+Nagel’s new facility is designed with healthcare and pharmaceuticals in mind.

“Pharmaceuticals in particular are highly-sensitive, time-critical products,” says Gereon Niemeier, Managing Director, Kuehne+Nagel South Africa. “Every minute these products spend on the tarmac exposes them to temperature fluctuations, physical damage, and loss. Our new facility addresses all these challenges to ensure product stability throughout the journey.”

“Our people have the expertise for plane-side access that other logistics providers don’t,” Niemeier points out. “In addition, the facility is so close to the charter parking area that we can provide in-person visibility resources, as well as a unique dollie solution, that greatly reduce the risk of ground handling errors as well as shipment claims. On-site monitoring protects product stability — whether temperature-controlled, high value or time critical — throughout the entire journey.

Latest stories

Related stories

First GLP-1 Pill for Obesity by Novo Nordisk Approved by FDA

The U.S. Food and Drug Administration – FDA on...

How High-Achievers Stay Future-Ready in Evolving Job Markets

Job markets today are transforming rapidly. In the past...

Proactive Risk Management as a Core Capability in Pharma Development

Risk management in pharma is often treated as a reactive compliance box-ticking exercise. This article argues for reframing risk as a strategic competitive advantage. It details proactive frameworks like the "Excipient Exclusion Filter," Decision Quality (DQ) matrices, and "pre-mortem" analyses that allow development teams to anticipate failure modes and engineer them out of the pipeline before they occur.

Rethinking Pipeline Value Beyond Peak Sales Forecasts

The traditional reliance on risk-adjusted Net Present Value (rNPV) and peak sales forecasts is failing to capture the true potential of modern pharmaceutical assets, particularly platform technologies. This article introduces holistic valuation frameworks like Real Options Analysis (ROA) and the Platform VISTA model, arguing for a shift toward valuing "strategic fit," "lifecycle potential," and the intangible equity of innovation engines.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »